ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: TH-PO926

Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-Boost of Inactivated Vaccine and Replication-Defective Viral Vectors Vaccine Against SARS-CoV-2 Among Hemodialysis Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Narongkiatikhun, Phoom, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
  • Ophascharoensuk, Vuddhidej, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand
  • Noppakun, Kajohnsak, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand

Vaccines to prevent SARS-CoV-2 infection are considered as the most promising approach for modulating the pandemic. It is unknown that those vaccines are effectual in maintenance hemodialysis (MHD) patients as demonstrated in healthy people.


We conducted an observational prospective trial involving all MHD patients at Chiang Mai University hospital, Chiang Mai, Thailand. The participants were received homologous Sinovac (SV-SV), homologous AZD1222 (AZ-AZ), or the heterologous prime-boost of SV-AZ. The immunogenicity was assessed by antibodies against the S1 receptor-binding domain (anti-RBD), and SARS-CoV-2 surrogate virus neutralization test (sVNT) at specific timepoints. The primary outcome was the seroconversion rate of sVNT at day 28 after complete vaccination. The secondary outcomes were the seroconversion rate of sVNT after the first dose, the level of sVNT and anti-RBD at specific timepoints, factor associated with seroconversion, and the adverse events of each vaccine regimen.


A total of 130 MHD participants were recruited. Among those, 16 (12.31%), 89 (68.46%), and 25 (19.23%) patients were received the SV-SV, AZ-AZ, and SV-AZ regimen, respectively. The seroconversion rate of sVNT at day 28 after the second dose were 68.75%, 78.65%, and 88.0% for SV-SV, AZ-AZ, and SV-AZ, respectively (P=0.289). The level of sVNT and anti-RBD was highest among SV-AZ (Figure 1a, b). Age and percent of plasma lymphocyte were associated with seroconversion. There were no serious adverse events reported in any vaccine groups.


Immunization with SV-SV, AZ-AZ, and SV-AZ could generate humoral immunity without any serious adverse events among MHD patients. Using the heterologous vaccine prime boost seemed to be more efficacious in term of inducing immunogenicity and further studies should be warranted.

Figure 1 Percentage of sVNT (a) and the level of anti-RBD (b) at day 28 after the second dose of each vaccine regimen.


  • Other NIH Support